Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linrodostat + Nivolumab in Advanced Solid Tumors (China)
NCT03792750Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linrodostat in malignant solid tumor, sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants Experiencing Adverse Events (AE) up to 2 years, Number of Participants Experiencing Serious Adverse Events (SAE) up to 2 years and 12 more. Started Dec 2018; status: completed.
02
Drugs
linrodostat
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT03792750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792750.